SLGL Sol-Gel Technologies Ltd.

12.89
-0.54  -4%
Previous Close 13.43
Open 13.52
Price To Book 4.49
Market Cap 262,794,463
Shares 20,387,468
Volume 20,512
Short Ratio
Av. Daily Volume 112,731
Stock charts supplied by TradingView

NewsSee all news

  1. Sol-Gel Announces Presentation of Data for its Topical Product Candidates for Acne and Rosacea at the 16th Annual Maui Derm for Dermatologists 2020 Meeting

    NESS ZIONA, Israel, Jan. 21, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies Ltd. (NASDAQ:SLGL) ("Sol-Gel" or the "Company") today announced the presentation of results from the Company's Phase 3 trials for its

  2. Sol-Gel Hosts Investor Call to Discuss Positive Results from Twyneo® Phase 3 Program in Acne Vulgaris

    Conference call with Sol-Gel management and U.S. key opinion leader today at 8:00 a.m. Eastern time NESS ZIONA, Israel, Jan. 08, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ:SLGL) will host a conference

  3. Sol-Gel Announces Initiation of SGT-210 Phase 1 Proof of Concept Study in Palmoplantar Keratoderma (PPK)

    NESS ZIONA, Israel, Jan. 02, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ:SLGL) today announced the initiation of a Phase 1 proof of concept clinical study of SGT-210, its novel, topical, epidermal

  4. Sol-Gel Announces Positive Top-Line Phase 3 Trial Results of Twyneo® for the Treatment of Acne Vulgaris

    All co-primary endpoints achieved in both Phase 3 clinical trialsTwyneo was well-tolerated and the majority of local skin reactions, when reported, were mild and improved over timeAdditional data to be shared during the

  5. Sol-Gel Technologies Reports Third Quarter 2019 Financial Results and Corporate Update

    Top-line generic product revenue of $4.7 million in the third quarterResults from TWIN Phase 3 trials in acne vulgaris remain on track for the fourth quarter of 2019 NESS ZIONA, Israel, Nov. 13, 2019 (GLOBE

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 trial to be initiated in 2020 with data due 2021.
SIRS-T
Acne
Phase 3 data met co-primary endpoints - December 30, 2019. NDA filing due 2H 2020.
Twyneo
Acne
Phase 3 top-line data met primary endpoints - July 8, 2019.
VERED (Epsolay)
Papulopustular rosacea
Proof of concept trial to commence 1Q 2020.
SGT-210
Palmoplantar keratoderma (PPK)
Phase 1 trial initiation announced January 2, 2019. Data due 1H 2021.
SGT-210
Palmoplantar keratoderma (PPK)

Latest News

  1. Sol-Gel Announces Presentation of Data for its Topical Product Candidates for Acne and Rosacea at the 16th Annual Maui Derm for Dermatologists 2020 Meeting

    NESS ZIONA, Israel, Jan. 21, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies Ltd. (NASDAQ:SLGL) ("Sol-Gel" or the "Company") today announced the presentation of results from the Company's Phase 3 trials for its

  2. Sol-Gel Hosts Investor Call to Discuss Positive Results from Twyneo® Phase 3 Program in Acne Vulgaris

    Conference call with Sol-Gel management and U.S. key opinion leader today at 8:00 a.m. Eastern time NESS ZIONA, Israel, Jan. 08, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ:SLGL) will host a conference

  3. Sol-Gel Announces Initiation of SGT-210 Phase 1 Proof of Concept Study in Palmoplantar Keratoderma (PPK)

    NESS ZIONA, Israel, Jan. 02, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ:SLGL) today announced the initiation of a Phase 1 proof of concept clinical study of SGT-210, its novel, topical, epidermal

  4. Sol-Gel Announces Positive Top-Line Phase 3 Trial Results of Twyneo® for the Treatment of Acne Vulgaris

    All co-primary endpoints achieved in both Phase 3 clinical trialsTwyneo was well-tolerated and the majority of local skin reactions, when reported, were mild and improved over timeAdditional data to be shared during the

  5. Sol-Gel Technologies Reports Third Quarter 2019 Financial Results and Corporate Update

    Top-line generic product revenue of $4.7 million in the third quarterResults from TWIN Phase 3 trials in acne vulgaris remain on track for the fourth quarter of 2019 NESS ZIONA, Israel, Nov. 13, 2019 (GLOBE